Company Overview - Seer Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, established on February 23, 2004, and listed on October 31, 2016 [2] - The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and R&D, production, and sales of self-developed in vitro diagnostic products [2] - The revenue composition is as follows: centralized SPD 45.10%, centralized IVD 33.43%, and pure sales 21.47% [2] Financial Performance - As of March 31, the number of shareholders is 46,600, an increase of 52.46% compared to the previous period; the average circulating shares per person is 4,099, a decrease of 34.40% [2] - For the first quarter of 2025, the company achieved operating revenue of 287 million yuan, a year-on-year decrease of 40.75%; the net profit attributable to the parent company was -14.32 million yuan, a year-on-year decrease of 553.66% [2] Stock Performance - On August 28, the stock price of Seer Medical fell by 2.02%, trading at 32.48 yuan per share, with a transaction volume of 319 million yuan and a turnover rate of 5.05%, resulting in a total market value of 6.204 billion yuan [1] - Year-to-date, the stock price has increased by 349.86%, with a 13.37% increase over the last five trading days, an 8.19% increase over the last 20 days, and a 165.36% increase over the last 60 days [1] - The company has appeared on the daily trading leaderboard 37 times this year, with the most recent appearance on August 26, where the net buying on the leaderboard was 146 million yuan, accounting for 18.85% of the total trading volume [1] Dividend Information - Since its A-share listing, Seer Medical has distributed a total of 27.0741 million yuan in dividends, with no dividends distributed in the last three years [3]

金融界消息，根据中登公司数据显示，截至上周最后一个交易日（8月15日），塞力医疗股东质押比例 占总股本9.23%，位居两市第989位。 数据显示，塞力医疗股东共质押1930.00万股，分为5笔，其中无限售股1930.00万股，质押总市值5.48亿 元。 资料显示，塞力斯医疗科技集团股份有限公司的主营业务是体外诊断试剂、体外诊断仪器的销售业务。 公司的主要产品是单纯销售、集约化IVD、集约化SPD。公司较早将IVD集约化业务升级布局SPD运营 业务，取得先发优势。同时基于公司早些年强大的IVD运营根基，凭借医疗供应领域二十余年的经验累 积和过硬实力荣登中国物流与采购联合会医疗器械供应链50强获奖企业名单，同时被授予《医药产品医 院院内物流服务规范》团体标准试点单位。公司董事长为温伟，总经理为王政。 从股票走势来看，塞力医疗近一年上涨 319.65%。 来源：金融界 ...

6月10日，塞力医疗今日收盘13.46元，上涨9.97%，最新市净率3.03，创59天以来新低，总市值25.71亿 元。 来源：金融界 塞力斯医疗科技集团股份有限公司的主营业务是体外诊断试剂、体外诊断仪器的销售业务。公司的主要 产品是单纯销售、集约化IVD、集约化SPD。公司较早将IVD集约化业务升级布局SPD运营业务，取得 先发优势。同时基于公司早些年强大的IVD运营根基，凭借医疗供应领域二十余年的经验累积和过硬实 力荣登中国物流与采购联合会医疗器械供应链50强获奖企业名单，同时被授予《医药产品医院院内物流 服务规范》团体标准试点单位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 截至2025年一季报，共有7家机构持仓塞力医疗，其中QFII4家、其他3家，合计持股数4042.93万股，持 股市值4.19亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-11.34-12.293.0325.71亿行业平均 45.2434.022.09112.61亿行业中值28.5 ...

5月12日，塞力医疗今日收盘11.16元，上涨1.73%，最新市净率2.52，总市值21.32亿元。 来源：金融界 塞力斯医疗科技集团股份有限公司的主营业务为集约化销售、单纯销售以及自主体外诊断产品的研发、 生产和销售。公司的主要产品为集约化IVD、集约化SPD等。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-9.40-10.192.5221.32亿行业平均 36.7728.301.81107.82亿行业中值27.5423.801.3158.44亿1漱玉平民-26.93-24.772.4346.78亿3海王生 物-5.06-5.143.3761.31亿4柳药集团8.258.030.8968.64亿5九州通8.9510.500.99263.22亿6鹭燕医药 9.549.190.9831.78亿7英特集团10.7010.581.1955.58亿8国药股份11.2111.211.28224.24亿9南京医药 11.4111.7 ...

5月9日，塞力医疗今日收盘10.97元，下跌4.94%，最新市净率2.47，总市值20.95亿元。 股东方面，截至2025年3月31日，塞力医疗股东户数46600户，较上次增加16035户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-9.24-10.012.4720.95亿行业平均 36.7828.221.80107.38亿行业中值27.4324.131.3158.16亿1漱玉平民-26.84-24.692.4246.62亿3海王生 物-5.04-5.113.3661.04亿4柳药集团8.268.030.8968.68亿5九州通8.9010.440.99261.70亿6鹭燕医药 9.539.180.9831.74亿7英特集团10.6410.521.1855.27亿8国药股份11.2411.231.28224.69亿9南京医药 11.3811.750.9667.04 ...

4月21日，塞力医疗今日收盘9.87元，上涨2.39%，最新市净率1.93，总市值18.85亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入14.20亿元，同比-7.15%；净利润-56025062.27 元，同比-1368.70%，销售毛利率19.89%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-8.94-11.891.9318.85亿行业平均 23.6322.711.80104.91亿行业中值18.9916.091.3056.98亿1漱玉平民-103.9232.812.1043.66亿3海王生 物-3.46-3.551.9859.99亿4柳药集团7.847.840.9067.01亿5鹭燕医药8.548.870.9530.65亿6国药股份 11.1111.111.30222.13亿7英特集团11.2911.041.2353.96亿8南京医药11.3611.360.9564.81亿9九州通 11.7311.040.97240.02亿10健之佳13.127.501.1231.06亿11百洋医药13.6715.654.65102.71亿 来源：金融界 股东方面，截至2024年 ...